Inorbit Therapeutics AB
Inorbit Therapeutics AB (InorbitTX) was founded in 2015. It is a privately owned virtual Drug Discovery and Development company based in the BioVentureHub in Mölndal, near Gothenburg, Sweden. We focus our small molecule drug discovery and development expertise on areas with a high unmet medical need and an excellent market perspective with a special interest for Non Alcoholic Steato Hepatitis (NASH). InorbitTX applies a unique groundbreaking chemotype to generate its potential new drugs. This chemotype is specifically designed to mitigate the risk for Drug Induced Liver Injury (DILI), a major cause for drug failure in late stages of development and even after approval and marketing. Its current lead compound, the Farnesoid X Receptor (FXR) agonist IOT022, aimed for the treatment of NASH, shows excellent efficacy in a sub-chronic in vivo model with an excellent safety margin.
Our leaders have long and successful track records in drug discovery and Development.
Our CEO, Dr. Bert Benthem, born 1962
Our CSO, Dr. Robert Judkins, born 1972
Leadership is supported by the Board of Directors:
Bert Benthem, PhD, (chair, see above)
Wim Mol, Phd, CEO at Immunovo BV, a privately held company based in Den Bosch, The Netherlands. Wim carries over 20 years of international experience in general management, commercial and R&D positions in the pharmaceutical industry.
Louise Warme, MD, investment manager at ALMI Invest, Sweden’s most active venture capitalist investing in start-ups. Louise brings a broad experience from (pre-)clinical research, med-tech, and the investment milieu.
Johannes Bruski, PhD, partner in Astadis Capital, a private trading and investment group. Before establishing Astadis, Johannes was a partner in Allen & Overy LLP. After practicing in Frankfurt, Germany, he was seconded to their associated firm Khoshaim & Associates in Riyadh and resided there for the last ten years. He continues to support Khoshaim & Associates as a senior consultant, and he currently also serves as a special advisor to the Saudi Ministry of Commerce and Investment. He has worked on many private and public mergers, acquisitions and joint ventures, both for strategic and for venture capital/private equity investors, and on other corporate and structured finance transactions.